Chia‐Chi Lin

机构：National Taiwan University Hospital · ORCID：0000-0002-2573-5789

发表论文 177 篇 · 总被引 9393 次 · h-index 38

代表论文

• Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study (2023 · Cancer Discovery · 被引 118)
• Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study (2023 · Thyroid · 被引 61)
• Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors (2023 · Journal for ImmunoTherapy of Cancer · 被引 46)
• Sabatolimab in combination with spartalizumab in patients with non-small cell lung cancer or melanoma who received prior treatment with anti-PD-1/PD-L1 therapy: a phase 2 multicentre study (2024 · BMJ Open · 被引 19)
• Correction: Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors (2024 · Clinical Cancer Research · 被引 7)
• Amivantamab Monotherapy in Chemorefractory RAS / BRAF Wild-Type Metastatic Colorectal Cancer: Results From OrigAMI-1, an Open-Label, Phase Ib/II Study (2026 · Journal of Clinical Oncology · 被引 5)